Form 8-K - Current report:
SEC Accession No. 0001564590-21-033736
Filing Date
2021-06-22
Accepted
2021-06-22 08:30:14
Documents
12
Period of Report
2021-06-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K agle-8k_20210618.htm   iXBRL 8-K 40283
  Complete submission text file 0001564590-21-033736.txt   174332

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA agle-20210618.xsd EX-101.SCH 5764
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20210618_lab.xml EX-101.LAB 20227
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20210618_pre.xml EX-101.PRE 12075
5 EXTRACTED XBRL INSTANCE DOCUMENT agle-8k_20210618_htm.xml XML 3689
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 211033118
SIC: 2834 Pharmaceutical Preparations